Compare VRCA & FRMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRCA | FRMM |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.0M | 75.7M |
| IPO Year | 2018 | 2017 |
| Metric | VRCA | FRMM |
|---|---|---|
| Price | $3.78 | $3.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $13.83 | $9.50 |
| AVG Volume (30 Days) | 44.6K | ★ 96.6K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,577,000.00 | $6,547,000.00 |
| Revenue This Year | N/A | $177.58 |
| Revenue Next Year | $58.01 | $587.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $3.28 | $1.76 |
| 52 Week High | $9.82 | $7.15 |
| Indicator | VRCA | FRMM |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 26.83 |
| Support Level | N/A | $3.61 |
| Resistance Level | $5.94 | $5.12 |
| Average True Range (ATR) | 0.35 | 0.25 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 19.48 | 8.44 |
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Forum Markets Inc is a financial technology company focused on developing infrastructure that supports the origination, financing, and distribution of RWAs through blockchain-enabled capital markets. The company's business approach is centered on integrating traditional financial asset markets with blockchain-based infrastructure to enable the tokenization of income-generating real-world assets such as consumer credit, equipment finance assets, and other contractual cash-flow streams. It utilizes blockchain infrastructure, including Ethereum and related Layer-2 scaling protocols, to support the issuance, management, and potential secondary trading of tokenized financial instruments.